6 chapters across the catalog
Cocaine Vaccine, Adenovirus Platform Strategy
Researchers are testing a vaccine that uses an adenovirus to trick the immune system into attacking cocaine molecules, preventing the drug from reaching the brain. The "platform strategy" could eventually be applied to other addictions, including nicotine and heroin.
Nicotine Vaccine, Immune System Obfuscation and Liability
Public radio reports on a "nicotine vaccine" that uses antibodies to prevent nicotine from reaching the brain's reward centers. The hosts argue that calling it a "vaccine" is a misnomer designed to shield the manufacturers from legal liability if something goes wrong. They compare this to other "vaccines" for non-communicable issues like weight loss or depression.
Anti-Nicotine Vaccine, Pharmaceutical Indemnification, Nanoparticles
A new "anti-nicotine vaccine" uses nanoparticles to trigger an immune response against the chemical. The hosts point out that labeling the product a "vaccine" provides pharmaceutical companies with legal indemnification from the U.S. government, protecting them from lawsuits related to side effects.
Pharmaceutical Industry, Vaccine Development Report
A 2012 report from the pharmaceutical industry reveals that nearly 300 vaccines are currently in development, targeting conditions ranging from cat allergies to various cancers. The industry is expanding the definition of "vaccine" to include treatments for non-viral conditions like Alzheimer's and nicotine addiction. Specific projects mentioned include a cocaine abuse vaccine and a "NicVax" for smoking cessation.
The FDA is considering the approval of a "nicotine vaccine" developed by GlaxoSmithKline, which works as a chemical inhibitor rather than a traditional vaccine. Critics argue that because nicotine addiction is not a disease caused by a biological vector, the term "vaccine" is being misused for marketing purposes. The discussion predicts a future where "vaccines" are marketed for social behaviors like obesity or sexual orientation as the pharmaceutical industry seeks new revenue streams.
Pharmaceutical Vaccine Pipelines and FDA Leadership Connections
GlaxoSmithKline and other pharmaceutical companies are shifting focus toward vaccines as a primary profit center, including experimental treatments for nicotine addiction. The hosts discuss the appointment of Peggy Hamburg as the head of the FDA and her previous ties to the private sector. A personal anecdote mentions a connection to Hamburg's neighbor in Washington.
